Starboard Value to Oppose Bristol-Celgene Merger

The transcript discusses the opposition to a deal involving Celgene and Bristol, highlighting actions by Starboard and Wellington. Analysts suggest the deal may proceed due to a lack of alternatives, despite shareholder opposition. The sector is consolidating, with potential future deals. Starboard is actively campaigning against the deal, aiming to influence shareholder votes.

What strategies are expected from Starboard in their opposition to the deal?

Discuss the implications of the Celgene deal on the broader pharmaceutical sector.